The Spectrum of Fundus Autofluorescence Findings in Birdshot Chorioretinopathy

Table 1

Demographic characteristics.

Patients	Eye	Age	Gender	Diagnosis*	HLA A29	Treatment	VA	ERG**	OCT***
1	OD	50	Female	2001	Positive	Daclizumab	20/20	38	241
	OS						20/30	30	383
2	OD	48	Male	1997	Positive	MMF+CSA	20/50	35	562
	OS						20/20	30.5	241
3	OD	58	Female	2008	Positive	MMF+CSA	20/30	34.5
	OS						20/25	31.5
4	OD	59	Male	1998	Positive	MMF+CSA	20/20	35.7
	OS						20/25	31.9
5	OD	58	Female	2004	Positive	MMF+CSA	20/25	36.8	165
	OS						20/40	44.5	312
6	OD	69	Female	2007	Positive	IVIG	20/25	32.7
	OS						20/30	31.8
7	OD	53	Female	2006	Positive	MMF+CSA	20/20	29
	OS						20/20	27.8
8	OD	56	Female	2005	Positive	Daclizumab	20/20	31.5	213
	OS						20/20	30.5	217
9	OD	49	Female	2005	Positive	Adalimumab	20/20	27.5
	OS					Prednisone	20/20	26

*Year in which the diagnosis was made; **Implicit times (ms); ***Central macular thickness (microns).
VA: Best corrected visual acuity; ERG: electroretinogram; OCT: optical coherence tomography; MMF: mycophenolate mofetil; CSA: cyclosporine; IvIg: intravenous immunoglobulin.